MA47202A - Anticorps humains dirigés contre la toxine hémolysine a de s.aureus - Google Patents
Anticorps humains dirigés contre la toxine hémolysine a de s.aureusInfo
- Publication number
- MA47202A MA47202A MA047202A MA47202A MA47202A MA 47202 A MA47202 A MA 47202A MA 047202 A MA047202 A MA 047202A MA 47202 A MA47202 A MA 47202A MA 47202 A MA47202 A MA 47202A
- Authority
- MA
- Morocco
- Prior art keywords
- hemolysin
- aureus
- toxin
- directed against
- human antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762441786P | 2017-01-03 | 2017-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47202A true MA47202A (fr) | 2019-11-13 |
Family
ID=61054509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047202A MA47202A (fr) | 2017-01-03 | 2018-01-02 | Anticorps humains dirigés contre la toxine hémolysine a de s.aureus |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10463748B2 (fr) |
| EP (1) | EP3565835A1 (fr) |
| JP (2) | JP2020504759A (fr) |
| KR (1) | KR20190101435A (fr) |
| CN (1) | CN110167960B (fr) |
| AR (1) | AR110719A1 (fr) |
| AU (1) | AU2018206531A1 (fr) |
| BR (1) | BR112019013375A2 (fr) |
| CA (1) | CA3048989A1 (fr) |
| CL (1) | CL2019001836A1 (fr) |
| CO (1) | CO2019006902A2 (fr) |
| EA (1) | EA201991643A1 (fr) |
| IL (1) | IL267600A (fr) |
| MA (1) | MA47202A (fr) |
| MX (1) | MX2019007784A (fr) |
| MY (1) | MY199976A (fr) |
| PH (1) | PH12019501425A1 (fr) |
| TW (2) | TW202311284A (fr) |
| WO (1) | WO2018128973A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| WO2020106461A2 (fr) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anticorps anti-mertk et leurs méthodes d'utilisation |
| CN109400704B (zh) * | 2018-11-14 | 2020-07-21 | 珠海泰诺麦博生物技术有限公司 | 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用 |
| CA3110377A1 (fr) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-staphylococcus et leurs utilisations |
| JP2022519631A (ja) | 2019-02-12 | 2022-03-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法 |
| CN113966343A (zh) | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN113444172A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| JP7590791B2 (ja) * | 2020-10-27 | 2024-11-27 | ミリムジーン カンパニー，リミテッド | Ｗａｒｓ中和抗体及びその用途 |
| BR112023013790A2 (pt) * | 2021-01-11 | 2023-10-03 | Starmab Biologics Suzhou Co Ltd | Proteína de ligação a antígeno dirigida à alfa-toxina de staphylococcus aureus e aplicação da mesma |
| WO2022199527A1 (fr) * | 2021-03-22 | 2022-09-29 | 星济生物(苏州)有限公司 | Protéine de liaison à l'antigène ciblant la protéine hémolysine de streptococcus pneumoniae et son utilisation |
| WO2023208123A1 (fr) * | 2022-04-28 | 2023-11-02 | 珠海泰诺麦博制药股份有限公司 | Anticorps monoclonal entièrement humain se liant spécifiquement à la toxine hla de staphylococcus aureus |
| CN115894674B (zh) * | 2022-12-20 | 2023-07-25 | 厦门润康源生物科技有限公司 | 一种用于检测冠状病毒的抗体及制备方法和应用 |
| CN116789814B (zh) * | 2023-06-27 | 2024-03-29 | 重庆原伦生物科技有限公司 | 一种特异性结合金黄色葡萄球菌α-溶血素的抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| GB8426463D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| JP2003503015A (ja) | 1999-05-03 | 2003-01-28 | メダレツクス・インコーポレーテツド | スタフィロコッカス・アウレウスに対するヒト抗体 |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (fr) | 2004-04-20 | 2013-11-06 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (fr) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions et procedes destines au traitement du cancer |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| JP2009539979A (ja) | 2006-06-12 | 2009-11-19 | ナビ バイオファーマシューティカルズ | ブドウ球菌感染症を治療および予防するための、α毒素の使用 |
| US20180221466A9 (en) | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| WO2009140236A2 (fr) | 2008-05-12 | 2009-11-19 | Strox Biopharmaceuticals, Llc | Préparations d'anticorps spécifiques de staphylococcus aureus |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| EP2284193A1 (fr) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Anticorps monoclonal humain contre l'alpha-toxine dérivée du Staphylococcus aureus, et son utilisation pour le traitement ou la prévention de la formation des abcès |
| AU2011295702A1 (en) | 2010-09-02 | 2013-04-04 | Excelimmune, Inc. | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof |
| RS58190B2 (sr) | 2011-02-08 | 2021-08-31 | Medimmune Llc | Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene |
| US20140286960A1 (en) | 2011-07-28 | 2014-09-25 | Cangene Corporation | Staphlococcus aureus alpha-hemolysin antibodies |
| WO2013093693A1 (fr) * | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Anticorps spécifiques de staphylococcus aureus et leurs utilisations |
| US9914767B2 (en) | 2012-04-17 | 2018-03-13 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody |
| ES2912267T3 (es) | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| CN105873946A (zh) * | 2013-10-17 | 2016-08-17 | 阿尔萨尼斯生物科学有限责任公司 | 交叉反应性金黄色葡萄球菌抗体序列 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TWI701258B (zh) * | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| AU2016249837A1 (en) | 2015-04-17 | 2017-09-28 | Arsanis Biosciences Gmbh | Anti-staphylococcus aureus antibody combination preparation |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
-
2017
- 2017-12-29 TW TW111136305A patent/TW202311284A/zh unknown
- 2017-12-29 TW TW106146395A patent/TWI781130B/zh not_active IP Right Cessation
-
2018
- 2018-01-02 MY MYPI2019003631A patent/MY199976A/en unknown
- 2018-01-02 MA MA047202A patent/MA47202A/fr unknown
- 2018-01-02 KR KR1020197022441A patent/KR20190101435A/ko not_active Withdrawn
- 2018-01-02 JP JP2019536141A patent/JP2020504759A/ja active Pending
- 2018-01-02 US US15/860,174 patent/US10463748B2/en active Active
- 2018-01-02 MX MX2019007784A patent/MX2019007784A/es unknown
- 2018-01-02 CN CN201880005378.7A patent/CN110167960B/zh not_active Expired - Fee Related
- 2018-01-02 CA CA3048989A patent/CA3048989A1/fr active Pending
- 2018-01-02 BR BR112019013375-5A patent/BR112019013375A2/pt not_active IP Right Cessation
- 2018-01-02 EA EA201991643A patent/EA201991643A1/ru unknown
- 2018-01-02 WO PCT/US2018/012044 patent/WO2018128973A1/fr not_active Ceased
- 2018-01-02 EP EP18701825.4A patent/EP3565835A1/fr not_active Withdrawn
- 2018-01-02 AU AU2018206531A patent/AU2018206531A1/en not_active Abandoned
- 2018-01-03 AR ARP180100006A patent/AR110719A1/es not_active Application Discontinuation
-
2019
- 2019-06-20 PH PH12019501425A patent/PH12019501425A1/en unknown
- 2019-06-24 IL IL267600A patent/IL267600A/en unknown
- 2019-06-27 CO CONC2019/0006902A patent/CO2019006902A2/es unknown
- 2019-07-02 CL CL2019001836A patent/CL2019001836A1/es unknown
- 2019-09-19 US US16/575,755 patent/US10940211B2/en active Active
-
2021
- 2021-01-27 US US17/159,920 patent/US11571482B2/en active Active
-
2022
- 2022-10-25 JP JP2022170270A patent/JP2023011710A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267600A (en) | 2019-08-29 |
| US11571482B2 (en) | 2023-02-07 |
| WO2018128973A1 (fr) | 2018-07-12 |
| JP2020504759A (ja) | 2020-02-13 |
| PH12019501425A1 (en) | 2020-06-15 |
| AU2018206531A1 (en) | 2019-07-25 |
| US20210162059A1 (en) | 2021-06-03 |
| CO2019006902A2 (es) | 2019-07-31 |
| CA3048989A1 (fr) | 2018-07-12 |
| TWI781130B (zh) | 2022-10-21 |
| CL2019001836A1 (es) | 2019-10-04 |
| EP3565835A1 (fr) | 2019-11-13 |
| CN110167960A (zh) | 2019-08-23 |
| US10940211B2 (en) | 2021-03-09 |
| AR110719A1 (es) | 2019-04-24 |
| US20200016275A1 (en) | 2020-01-16 |
| MY199976A (en) | 2023-12-01 |
| US20180214569A1 (en) | 2018-08-02 |
| TW202311284A (zh) | 2023-03-16 |
| MX2019007784A (es) | 2019-09-06 |
| CN110167960B (zh) | 2023-01-13 |
| US10463748B2 (en) | 2019-11-05 |
| EA201991643A1 (ru) | 2020-01-20 |
| JP2023011710A (ja) | 2023-01-24 |
| KR20190101435A (ko) | 2019-08-30 |
| BR112019013375A2 (pt) | 2020-02-11 |
| TW201837054A (zh) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3700416A4 (fr) | Capteurs d'analyte préconnectés | |
| IL267600A (en) | Human antibodies to the hemolysin a toxin of s. aureus | |
| EP3665140C0 (fr) | Mélanges agricoles | |
| EP3629937C0 (fr) | Capteur vasculaire ultrasonore implantable | |
| EP3687374A4 (fr) | Capteur physiologique intraoculaire | |
| EP3740508A4 (fr) | Anticorps et variants associés dirigés contre tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| EP3589313A4 (fr) | Anticorps anti-tigit | |
| EP3813710A4 (fr) | Analyse d'ajustement d'implant | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| EP3568192A4 (fr) | Valves de cathéter | |
| DK3649152T3 (da) | ROR1-antistoffer | |
| EP3672900A4 (fr) | Amplificateur de levage d'élément de construction | |
| EP3777957A4 (fr) | Structure de connexion médicale | |
| EP3617231A4 (fr) | Anticorps anti-gpc-1 | |
| EP3692072A4 (fr) | Anticorps anti-hla-dq2.5 | |
| EP3847438A4 (fr) | Capteurs rétrographiques | |
| MA51134A (fr) | Anticorps anti-alpha-synucléine | |
| EP3805223A4 (fr) | Dérivé de 2,3-dihydro-1h-pyrrolizine-7-formamide et son application | |
| MA51135A (fr) | Anticorps anti-alpha-synucléine | |
| EP3837286A4 (fr) | Anticorps dirigés contre znt8 humain | |
| EP3760247A4 (fr) | Séparateur de toxines | |
| EP3648575C0 (fr) | Système de plantation pour surface d'un bâtiment | |
| MA50654A (fr) | Anticorps anti-pacap | |
| MA49257A (fr) | Anticorps anti-trkb |